



# The bacterial pigment pyocyanin inhibits the NLRP3 inflammasome through intracellular reactive oxygen and nitrogen species

Received for publication, November 27, 2017, and in revised form, February 5, 2018. Published, Papers in Press, February 6, 2018, DOI 10.1074/jbc.RA117.001105

Sebastian Virreira Winter and Arturo Zychlinsky<sup>1</sup>

From the Max Planck Institute for Infection Biology, Charitéplatz 1, 10117 Berlin, Germany

Edited by Luke O'Neill

**Inflammasomes** are cytosolic complexes that mature and secrete the inflammatory cytokines interleukin 1 $\beta$  (IL-1 $\beta$ ) and IL-18 and induce pyroptosis. The NLRP3 (NACHT, LRR, and PYD domains–containing protein 3) inflammasome detects many pathogen- and danger-associated molecular patterns, and reactive oxygen species (ROS)/reactive nitrogen species (RNS) have been implicated in its activation. The phenazine pyocyanin (PCN) is a virulence factor of *Pseudomonas aeruginosa* and generates superoxide in cells. Here we report that PCN inhibits IL-1 $\beta$  and IL-18 release and pyroptosis upon NLRP3 inflammasome activation in macrophages by preventing speck formation and Caspase-1 maturation. Of note, PCN did not regulate the AIM2 (absent in melanoma 2) or NLRC4 inflammasomes or tumor necrosis factor (TNF) secretion. Imaging of the fluorescent glutathione redox potential sensor Grx1-roGFP2 indicated that PCN provokes cytosolic and nuclear but not mitochondrial redox changes. PCN-induced intracellular ROS/RNS inhibited the NLRP3 inflammasome posttranslationally, and hydrogen peroxide or peroxytrinitrite alone were sufficient to block its activation. We propose that cytosolic ROS/RNS inhibit the NLRP3 inflammasome and that PCN's anti-inflammatory activity may help *P. aeruginosa* evade immune recognition.

Inflammation is an essential response to infection or tissue damage. Pattern recognition receptors detect infection or injury and initiate a process that culminates in cytokine secretion to orchestrate the recruitment of immune cells to the inflammatory site. Inflammasomes are cytosolic multiprotein complexes that regulate the secretion of the inflammatory cytokines IL-1 $\beta$ <sup>2</sup> and IL-18 and a type of cell death called pyroptosis.

The authors declare that they have no conflicts of interest with the contents of this article.

✂ Author's Choice—Final version free via Creative Commons CC-BY license. This article contains Figs. S1–S5.

<sup>1</sup> To whom correspondence should be addressed. Tel.: 49-30-28460-302; E-mail: zychlinsky@mpiib-berlin.mpg.de.

<sup>2</sup> The abbreviations used are: IL, interleukin; ASC, apoptosis-associated speck-like protein containing a CARD; ROS, reactive oxygen species; RNS, reactive nitrogen species; PCN, pyocyanin; 1-HP, 1-hydroxy-phenazine; BMDM, bone marrow–derived macrophage; PCA, phenazine-1-carboxylic acid; LPS, lipopolysaccharide; LDH, lactate dehydrogenase; TNF, tumor necrosis factor; CHX, cycloheximide; CM-H<sub>2</sub>-DCFDA, 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate acetyl ester; DHE, dihydroethidium; NAC, *N*-acetyl-L-cysteine; NO, nitric oxide; FCS, fetal calf serum; Bicine, *N,N*-bis(2-hydroxyethyl)glycine; ANOVA, analysis of variance; IRES, internal ribosomal entry site.


Multiple pattern recognition receptors engage the assembly of inflammasomes, including the NOD- and AIM2-like receptors. All inflammasomes contain Caspase-1 and many engage the adapter protein apoptosis-associated speck-like protein containing a CARD (ASC). A well studied sensor is NACHT, LRR, and PYD domains–containing protein 3 (NLRP3), which is central in host microbial defense and in the pathogenesis of many diseases like atherosclerosis, diabetes, and Alzheimer's disease (1).

Macrophages require two steps to activate the NLRP3 inflammasome: transcriptional priming and a stimulus triggering inflammasome assembly. Many molecules activate the NLRP3 inflammasome, although it remains elusive how these chemically diverse molecules are recognized. It was proposed that NLRP3 is an ion sensor because most stimuli trigger potassium efflux (2). An alternative model posits reactive oxygen species (ROS) and nitrogen species (RNS) as the common NLRP3 inflammasome trigger (3, 4). Indeed, pharmacological or RNAi-based inhibition of the NADPH oxidase NOX2 blocks the NLRP3 inflammasome (3, 4). However, mice and patients with mutant NOX2 show normal or even increased NLRP3 inflammasome activation (4). Regardless, redox mechanisms regulate transcription of IL-1 $\beta$  and NLRP3 as well as IL-1 $\beta$  secretion and Caspase-1 activity (4). Moreover, mitochondrial ROS are essential for NLRP3 activation (5).

Nigericin, ATP, and crystalline substances such as silica are frequently used NLRP3 activators. Nigericin is a bacterial H<sup>+</sup>/K<sup>+</sup> antiporter, ATP released by dead cells is sensed by P2X purinoceptor 7, and crystals destabilize the phagosome (1). All of these stimuli trigger NLRP3 inflammasome assembly by inducing K<sup>+</sup> efflux (2). The NLRC4 inflammasome detects flagellin and the type III secretion system and is essential to sense pathogenic bacteria. The AIM2 inflammasome detects cytosolic double-stranded DNA and senses intracellular microbes.

The opportunistic pathogen *Pseudomonas aeruginosa* causes nosocomial infections and attacks immunocompromised hosts. This microbe has multiple pathogenic mechanisms that contribute to pathogenesis, including the blue pigment pyocyanin (PCN) (6). PCN is a membrane-permeable secreted phenazine that produces ROS/RNS and is an essential virulence factor (7, 8). It mainly produces superoxide anions by non-enzymatic transfer of electrons from NADH and NADPH to oxygen (9). PCN is exclusively produced by *P. aeruginosa* and is anti-bacterial against other microbes, whereas *Pseudomonas*

## Pyocyanin inhibits the NLRP3 inflammasome



**Figure 1. Pyocyanin blocks Caspase-1 maturation and IL-1 $\beta$  release in response to NLRP3 activation.** A–D, BMDMs were first primed for 3 h with LPS and then incubated with 0, 10, 20, 40, 60, 80, or 100  $\mu$ M PCN for 15 min before activating NLRP3 with nigericin (A and B) or ATP (C) for 1 h or silica (D) for 2 h. We quantified IL-1 $\beta$  and IL-18 (ELISA) and pyroptosis (intracellular LDH content) at the indicated time. E, we pretreated LPS-primed BMDMs with 0, 40, or 100  $\mu$ M PCN for 15 min before activating NLRP3 with nigericin for 45 min. We collected supernatants and prepared whole-cell lysates 45 min after activation for Western blotting. Arrows indicate pro-Caspase 1 and asterisks the active p20 fragment. The graphs show mean  $\pm$  S.D. from one representative experiment of three independent replicates. The Western blot is from one representative experiment of two independent replicates. Repeated measures one-way ANOVA was performed on three independent experiments for statistical analysis. *Pyo*, pyocyanin.

strains are resistant to the phenazine (10). PCN also regulates iron uptake, redox homeostasis, and biofilm formation (7, 9). In the host, this phenazine inhibits cell growth and ciliary movements and induces cell death and cytokine release (7, 9, 11, 12). Notably, PCN oxidizes GSH, the most abundant thiol in cells and an important antioxidant. *P. aeruginosa* also secretes other phenazines, like 1-hydroxy-phenazine (1-HP) and the PCN precursor phenazine-1-carboxylic acid (PCA).

Here we show for the first time that PCN-dependent redox changes block the NLRP3 inflammasome in bone marrow-derived macrophages (BMDMs). PCN inhibits NLRP3 post-translationally and ROS/RNS-dependently and acts upstream of speck formation and Caspase-1 maturation. We demonstrate a previously unrecognized anti-inflammatory effect of PCN and show that excessive ROS/RNS production silences the NLRP3 inflammasome.

## Results

### PCN blocks NLRP3-dependent Caspase-1 maturation and IL-1 $\beta$ release


We examined whether PCN interferes with inflammasome activation by nigericin at concentrations it has in the sputum of cystic fibrosis patients (13). A short preincubation of LPS-primed BMDMs with PCN strongly reduced secretion of both IL-1 $\beta$  and IL-18 in a concentration-dependent manner (Fig. 1A). We also quantified intracellular lactate dehydrogenase

(LDH) as a proxy for pyroptosis. As expected, NLRP3 activation reduced the LDH content to 50% compared with untreated cells (Fig. 1B). Notably, PCN rescued the cells from pyroptosis, as shown by the retention of intracellular LDH. PCN also inhibited IL-1 $\beta$  release in response to ATP (Fig. 1C) and silica (Fig. 1D). Importantly, PCN inhibited Caspase-1 processing and maturation of IL-1 $\beta$ , both hallmarks of inflammasome activation (Fig. 1E). PCN did not affect the levels of pro-IL-1 $\beta$  or NLRP3. These data show that PCN inhibits Caspase-1 maturation and the release of IL-1 $\beta$  and IL-18 in response to various NLRP3 inflammasome activators.

### PCN inhibits the NLRP3 inflammasome specifically

Because Caspase-1 and ASC are common to multiple inflammasomes, we tested which of these are blocked by PCN. We infected BMDMs with *Shigella flexneri* to activate NLRC4 or transfected the cells with double-stranded DNA to activate AIM2. PCN had almost no effect on IL-1 $\beta$  secretion after *S. flexneri* infection but led to minimal but significant inhibition of NLRC4 when used at the highest concentration of 100  $\mu$ M. In contrast, PCN reduced AIM2 activation in response to cytosolic DNA mildly but not significantly (Fig. 2A). Furthermore, PCN did not rescue cells from NLRC4- or AIM2-dependent pyroptosis (Fig. 2B).

PCN did not block, but even slightly increased, TNF secretion upon LPS stimulation of BMDMs, suggesting that PCN




**Figure 2. Pyocyanin inhibits activation of the NLRP3 inflammasome specifically.** A and B, LPS-primed BMDMs were treated with 0, 20, 40, 60, 80, or 100  $\mu\text{M}$  PCN for 15 min before activating NLRP3 with nigericin for 1 h, NLR4 by infection with *S. flexneri* for 1 h, and AIM2 by transfection of poly(dA:dT) and incubation for 2 h. We quantified IL-1 $\beta$  (ELISA) (A) and pyroptosis (intracellular LDH contents) (B) after the indicated times. C and D, BMDMs were first pretreated with 0, 20, 40, 60, 80, or 100  $\mu\text{M}$  PCN for 15 min and then stimulated with LPS for 2 h. We quantified TNF (ELISA) (C) and pyroptosis (intracellular LDH content) (D) after 2 h. The graphs show mean  $\pm$  S.D. from one representative experiment of three (A and B) or four (C and D) independent replicates. Repeated measures one-way ANOVA was performed on three (A and B) or four (C and D) independent experiments for statistical analysis. *n.s.*, not significant.

is not a general inhibitor of cytokine production (Fig. 2C). Even at high concentrations, PCN was not toxic, as shown by the retention of intracellular LDH (Fig. 2D). Together, these data show that PCN interferes specifically with the NLRP3 inflammasome.

### PCN prevents inflammasome speck formation posttranslationally

PCN does not interfere with transcription or translation in our setting because it did not affect TNF secretion or IL-1 $\beta$  and NLRP3 levels. It is important to stress that, in the experiments presented here, we first primed the macrophages with LPS to trigger all required transcriptional responses before we added pyocyanin for only a short timeframe to focus on posttranslational effects of PCN. Nevertheless, we determined the effect of PCN on the mRNA levels of diverse pro-inflammatory cytokines in BMDMs. PCN did not influence cytokine transcription, irrespective of whether it was added after (Fig. S1A) or before (Fig. S1B) LPS-mediated priming. To confirm that PCN blocks NLRP3 activation posttranslationally, we show that the protein synthesis inhibitor cycloheximide (CHX) did not affect




**Figure 3. Pyocyanin prevents inflammasome speck formation posttranslationally.** A, we first pretreated LPS-primed BMDMs with the indicated concentrations of the translation inhibitor CHX for 15 min and then incubated them with 0, 20, 40, 60, 80, or 100  $\mu\text{M}$  of PCN for another 15 min. Subsequently, we activated NLRP3 with nigericin for 1 h and quantified IL-1 $\beta$  (ELISA) and pyroptosis (intracellular LDH contents). Repeated measures two-way ANOVA with Bonferroni's multiple comparison test was performed on three independent experiments for statistical analysis. B, we treated LPS-primed BMDMs expressing ASC-Grx1-roGFP2 with 0, 40, or 60  $\mu\text{M}$  of PCN for 15 min. Then we activated NLRP3 with nigericin and quantified speck formation microscopically by imaging once a minute for 1 h. We calculated the percentage of cells showing a speck and used two-way repeated measures ANOVA with correction for multiple comparisons test (Dunnett) for statistical analysis. The corrected *p* values are 0.0079 for 0 versus 40  $\mu\text{M}$  PCN and 0.0012 for 0 versus 60  $\mu\text{M}$  PCN. C, we treated LPS-primed BMDMs expressing Fv'Fvls-ASC with 0, 20, 40, 60, 80, or 100  $\mu\text{M}$  PCN for 15 min and induced speck formation with 500 nm B/B homodimerizer (AP20187). Repeated measures one-way ANOVA was performed on three independent experiments for statistical analysis. The graphs in A and C show means  $\pm$  S.D. and are from one representative experiment of three independent replicates. The graph in B shows means  $\pm$  S.D. from four independent experiments. *n.s.*, not significant.

the inhibition of IL-1 $\beta$  secretion and pyroptosis (Fig. 3A). CHX was effective because it ablated TNF release in response to LPS (Fig. S2A).

Speck formation is a hallmark of NLRP3 inflammasome activation in response to classical activators such as nigericin and occurs upstream of Caspase-1 processing. To observe speck formation, we expressed a fusion protein of ASC and the glutathione redox potential sensor Grx1-roGFP2, which is a variant of the redox-sensitive green fluorescent protein roGFP2 and reversibly changes its fluorescence properties upon glutathione oxidation (Fig. S2B) (14). PCN significantly and dose-dependently reduced the percentage of cells with a visible speck in response to nigericin, suggesting that this compound interferes either with the interaction of NLRP3 with ASC or an upstream event (Fig. 3B).

To confirm that the effect of PCN was upstream of speck formation, we quantified IL-1 $\beta$  release upon artificial ASC aggregation. Fusions of caspases with the peptidyl-prolyl cis-trans isomerase FKBP12 induce cell death upon addition of a chemical dimerizer that has two FKBP12-binding domains (15). Analogously, we fused two copies of FKBP12<sub>V36</sub> to ASC to generate Fv'Fvls-ASC, which dimerizes upon addition of the

## Pyocyanin inhibits the NLRP3 inflammasome



**Figure 4. Pyocyanin inhibits the NLRP3 inflammasome through the production of ROS/RNS.** *A*, we loaded BMDMs with 5 μM CM-H<sub>2</sub>-DCFDA or DHE (oxidation-sensitive dyes) before incubating them with 0, 20, 40, 60, 80, or 100 μM PCN for 30 min. We quantified the fluorescence by flow cytometry. *MFI*, mean fluorescence intensity. *B*, we treated BMDMs expressing Grx1-roGFP2 in the cytosol (*black*), the mitochondria (*red*), the nucleus (*blue*), or at the plasma membrane (*orange*) with 40 μM PCN and recorded the sensor fluorescence. We calculated the percentage of oxidized sensor by determining the dynamic range at the end of the stimulation. Graphs indicate the median oxidation of all cells analyzed for 1 h. Bar graphs indicate the mean oxidation of Grx1-roGFP2 + S.D. at the indicated time points. *C* and *D*, we incubated LPS-primed BMDMs with MnTMPyP or NAc for 5 min. Then we introduced ROS/RNS by adding PCN, hydrogen peroxide, or peroxynitrite for 15 min and activated NLRP3 with nigericin for 1 h. The graphs in *A* show geometric mean ± S.E. from one representative experiment of three independent replicates. The graphs in *B* show mean ± S.D. from one representative experiment of three independent replicates. The graphs in *C* and *D* show mean ± S.D. from three independent experiments. Repeated measures one-way ANOVA with Bonferroni's multiple comparison test was performed on three independent experiments for statistical analysis. *n.s.*, not significant.

synthetic, cell-permeable ligand AP20187. We expressed this fusion protein in BMDMs and showed that chemically triggered dimerization of ASC results in IL-1β release (Fig. 3C). Notably, PCN did not interfere with IL-1β release and pyroptosis upon artificial ASC dimerization (Fig. S2C). These data suggest that PCN inhibits events upstream of speck formation.

### Pyocyanin inhibits the NLRP3 inflammasome through the production of ROS/RNS

We exposed BMDMs loaded with the ROS/RNS-detecting dyes CM-H<sub>2</sub>-DCFDA or dihydroethidium (DHE) to increasing PCN concentrations to confirm that PCN, like in other cells, causes ROS/RNS production in macrophages (Fig. 4A) (7). CM-H<sub>2</sub>-DCFDA preferentially senses peroxynitrite and the hydroxyl radical, whereas DHE primarily detects superoxide. Oxidation of both dyes indicated that PCN induced various ROS/RNS types. Besides PCN, 1-HP and, to a lesser extent, also PCA, but not phenazine, induced intracellular ROS (Fig. S3A).

To determine which intracellular sites are oxidized by PCN, we targeted the genetically encoded GSH redox potential sensor Grx1-roGFP2 to the cytosol, the nucleus, the mitochondria, or the plasma membrane of BMDMs by fusing it with the nuclear localization signal from SV40, the mitochondrial localization signal from ATP synthase protein 9 from *Neurospora crassa* or the C-terminal CAAX domain of human KRas, respectively. PCN oxidized GSH in the cytosol, the nucleus, and at the plasma membrane but, surprisingly, not in mitochondria, as quantified by time-lapse microscopy and ratiometric analysis

(Fig. 4B). Representative images of the ratiometric analysis at 0 or 30 min after PCN treatment are shown in Fig. S4A. We also quantified the mitochondrial glutathione redox potential reported to be increased in response to nigericin challenge, a strong NLRP3 activator (16–20). Surprisingly, nigericin decreased mitochondrial GSH oxidation (Fig. S4B).

Finally, we pretreated BMDMs with two cell-permeable ROS/RNS scavengers: the cysteine-containing *N*-acetyl-L-cysteine (NAC) and the porphyrin MnTMPyP. NAC scavenges ROS/RNS and replenishes the intracellular GSH pool, whereas MnTMPyP is a superoxide dismutase mimetic. MnTMPyP also scavenges peroxynitrite and, under reducing conditions, also nitric oxide (NO) (21). Neither of the scavengers alone prevented the inhibitory effect of PCN on IL-1β release (Fig. 4C). In combination, however, NAC and MnTMPyP abrogated PCN's effect. Furthermore, ROS/RNS are sufficient to interfere with NLRP3 activation because both hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) and peroxynitrite (ONOO<sup>-</sup>) efficiently inhibited IL-1β secretion in response to nigericin, and addition of NAC or MnTMPyP rescued the cytokine release (Fig. 4D). In line with a requirement for ROS/RNS to inhibit NLRP3, 1-HP, and, to a lesser extent, PCA, but not phenazine, blocked the NLRP3 inflammasome (Fig. S3B). The data show that phenazines inhibit NLRP3 activation by producing intracellular ROS/RNS. To investigate whether NLRP3 itself may be reversibly oxidized, we differentially alkylated cysteines in BMDM lysates with the cysteine-reactive isobaric tag iodoTMT and found that, among the six cysteines of NLRP3 analyzed, several

showed increased oxidation upon treatment with PCN (Fig. S5).

## Discussion

We show that PCN specifically blocked activation of the NLRP3 inflammasome upstream of speck formation. PCN did not interfere with conventional secretion or the activation of the NLRC4 or AIM2 inflammasomes. In contrast to the current view that ROS/RNS can activate NLRP3 (1), excessive oxidation by PCN inhibits this inflammasome. Our data show that PCN inhibits NLRP3 through intracellular ROS/RNS and GSH oxidation in compartments other than mitochondria. Moreover, intracellular ROS/RNS were sufficient to inhibit activation of NLRP3. Our data suggest that PCN does not interfere with events downstream of sensor activation because inflammasome signaling merges at ASC, and IL-1 $\beta$  release by artificial ASC dimerization remained unaffected (1).

Our findings demonstrate an unanticipated anti-inflammatory potential of PCN. PCN may also be anti-inflammatory by inducing neutrophil apoptosis and inhibiting the NADPH oxidase (7, 9). During the preparation of this manuscript, a study reported that PCN inhibits activation of the NLRP3 and NLRC4 inflammasomes in response to quorum sensing-deficient *P. aeruginosa* (22). However, this study did not investigate the contribution of ROS/RNS. Interestingly, PCN can also be pro-inflammatory by inducing oxidative stress, cytokine transcription, and the formation of neutrophil extracellular traps (7, 9, 12). Although short-term PCN treatment inhibits NLRP3 via a posttranslational mechanism, long-term exposure to oxidative stress may also influence transcription of inflammasome components or inflammatory cytokines (23). This pleiotropic effect reflects the complex physiology of ROS/RNS.

In contrast to previous studies in epithelial cells, lymphocytes, or neutrophils (24–27), PCN did not oxidize GSH in mitochondria. The observation that PCN-dependent oxidation of the cytosol in macrophages inhibits NLRP3 activation is in line with previous reports showing that increased superoxide content caused by a deficiency in cytosolic SOD1 blocks the NLRP3 inflammasome (1, 3–5, 28). The finding that the transcription factor Nrf2, which is an important mediator of the cellular antioxidant defense, is required for NLRP3 activation further underlines that excessive oxidation inhibits this inflammasome (29). Although we show that oxidative stress prevents NLRP3 inflammasome activation, this does not contradict previous studies showing that low levels of localized ROS/RNS, in particular within mitochondria, may trigger its activation. Thus, the subcellular localization of redox changes is crucial for NLRP3 activation. Of note, multiple studies report that mitochondrial ROS/RNS trigger NLRP3 activation, whereas others show that oxidation occurs downstream of inflammasome activation as a result of membrane damage (16–20, 30). Because inflammasome activation and pyroptosis occur shortly after each other and at different time points in individual cells, bulk analysis of cells most likely includes already dead cells, which could explain the discrepancies in the conclusions regarding whether ROS/RNS occur up- or downstream of inflammasome activation. Furthermore, many studies reporting that mitochondrial ROS activate NLRP3 based their conclusions on the

use of ROS scavengers or inducers, and they detected mitochondrial ROS only with the DHE-based superoxide indicator MitoSOX, which is enriched in mitochondria by the membrane potential. Nigericin is a K<sup>+</sup>/H<sup>+</sup> antiporter and disrupts the pH difference between the mitochondrial matrix and the intermembrane space. Because of compensatory mechanisms, the mitochondrial membrane potential may increase, whereas superoxide production decreases in response to nigericin (31–35). Notably, the increased membrane potential may also result in increased cationic dye enrichment, which complicates interpretation of MitoSOX-based measurements and may explain the contradictory results (36).

Only the combination of NAc and MnTMPyP prevented the PCN-mediated NLRP3 inhibition, suggesting that NO is relevant. This is consistent with the inhibition of NLRP3 by nitrosylation (37). Alternatively, PCN could interfere with the ubiquitination or phosphorylation of inflammasome components, which regulate NLRP3 activation (37–40). Ubiquitin-modifying enzymes and protein-tyrosine phosphatases contain catalytic cysteines prone to thiol oxidation (41). Interestingly, PTPN22, which dephosphorylates NLRP3, has an intracellular disulfide bond that could be redox-regulated (42).

The molecular target of PCN-induced oxidation responsible for the inhibition of the NLRP3 inflammasome remains to be determined. However, we present some evidence that NLRP3 itself may be reversibly oxidized at individual cysteine residues, which could explain why the PCN-mediated oxidative stress specifically blocks NLRP3 but not other inflammasomes.

PCN is an essential virulence factor, and the concentrations of this phenazine negatively correlate with lung function in cystic fibrosis patients (8, 13, 43). Interestingly, PCN-deficient, but not PCN-competent, *P. aeruginosa* induce IL-1 $\beta$  during lung infection (43). *P. aeruginosa* is sensed by many innate immune mechanisms, including NLRC4 and NLRP3 inflammasomes, and secretes two exotoxins that interfere with Caspase-1 (44–46). However, depending on the model, inflammasomes can be protective or cause excessive tissue damage in *P. aeruginosa* infections (47).

Quorum sensing is important for *P. aeruginosa* virulence and induces PCN in biofilms (44). We speculate that *P. aeruginosa* uses quorum sensing to promote PCN secretion and evade detection by NLRP3. This may explain why biofilms of *P. aeruginosa* establish infections effectively.

## Experimental procedures

### ROS detection by flow cytometry

We loaded BMDMs with 5  $\mu$ M 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate acetyl ester (CM-H2-DCFDA) or 5  $\mu$ M DHE (both from Thermo Fisher Scientific) in serum-free RPMI medium for 20 min at 37 °C. Cells were washed and resuspended in RPMI medium with 10% FCS and PCN, phenazine (both from Sigma-Aldrich), 1-HP (abcr GmbH), or PCA (Apollo Scientific Ltd). After 30 min, cells were centrifuged and resuspended in 0.2% FCS/PBS containing 0.6  $\mu$ M DRAQ7 (BioStatus) and analyzed with a MACSQuant Analyzer 10 flow cytometer. We analyzed the data with FlowJo v10 and excluded doublets and DRAQ7-positive cells.

# Pyocyanin inhibits the NLRP3 inflammasome

## Cell culture and inflammasome activation

We differentiated BMDMs from C57BL/6 mice (The Jackson Laboratory) for 7 days with L929 cell-conditioned medium. ASC and Grx1-roGFP2 constructs were retrovirally transduced to BMDMs 72 h after isolation.

Inflammasomes were activated with 10  $\mu\text{M}$  nigericin, 200  $\mu\text{g}/\text{ml}$  silica (both from Sigma-Aldrich), or 3 mM ATP (GE Healthcare) (all NLRP3), an overnight culture of *S. flexneri* strain M90T at a multiplicity of infection of 20 (NLRP4), or transfection of poly(dA:dT) (Invivogen) using Lipofectamine 2000 (Thermo Fisher Scientific) (AIM2). The B/B homodimerizer (AP20187) was from Clontech and CHX from Sigma-Aldrich.

## LDH determination

We quantified LDH with the CytoTox 96 non-radioactive cytotoxicity assay (Promega), modified as follows. At the end of an experiment, the cells were washed and lysed with 1% IGEPAL CA-630/PBS to measure LDH. Untreated cells were used as a reference.

## ROS scavenging

We primed BMDMs with 100 ng/ml LPS (Enzo Life Sciences) for 3 h before adding either 10 mM NAC (Sigma-Aldrich), 200  $\mu\text{M}$  MnTMPyP (Enzo Life Sciences), or both for 5 min. We added 60  $\mu\text{M}$  PCN, 100  $\mu\text{M}$   $\text{H}_2\text{O}_2$  (Sigma-Aldrich), or 100  $\mu\text{M}$  peroxyxynitrite (Merck Millipore) for 15 min before activating NLRP3 with 10  $\mu\text{M}$  nigericin.

## Cysteine oxidation assay

We transduced BMDMs during differentiation with a retrovirus to express FLAG-tagged mouse NLRP3. We primed differentiated BMDMs with 100 ng/ml LPS (Enzo Life Sciences) for 3 h before adding either 100  $\mu\text{M}$  PCN or DMSO as a control. Cells were washed with PBS and lysed in 50 mM Bicine (pH 8.0) with 8 M urea, 1% IGEPAL CA-630, 5 mM EDTA, and one reagent of the iodoTMTsixplex (4 mM, Thermo Fisher Scientific) for 1 h. Residual free thiols were scavenged by addition of 10 mM iodoacetamide for 15 min, and proteins were precipitated with acetone at a final concentration of 80% for 24 h at  $-20^\circ\text{C}$ . We washed the protein pellets twice with 80% acetone and resuspended the proteins in 50 mM Bicine (pH 8.0) with 8 M urea, 10 mM EDTA, and 800 mM NaCl. Initially oxidized cysteines were reduced by 1 mM tris(2-carboxyethyl)phosphine for 10 min and then alkylated with another reagent of the iodoTMTsixplex (4 mM) for 1 h. FLAG-tagged mouse Nlrp3 was enriched by anti-FLAG M2 affinity-agarose gel for 30 min at  $4^\circ\text{C}$ . The slurry was washed three times with 50 mM Bicine (pH 8.0) with 0.8 M urea, 1 mM EDTA, and 80 mM NaCl, and proteins were eluted from the beads with 0.1 M glycine (pH 3.5) and immediately mixed with 500 mM Bicine to neutralize the pH. We then digested the proteins with LysC and trypsin (Sigma-Aldrich) in the presence of 2 M urea for 24 h. Samples were then desalted by stage tipping and analyzed by MS/MS with an Q Exactive HF-X instrument (Thermo Fisher Scientific). Mass spectrometry data were processed with the MaxQuant software.

## Imaging

We imaged BMDMs in ibidi dishes in live-cell imaging solution (Thermo Fisher Scientific) supplemented with 2% FCS, 2 mM L-glutamine, 100 units/ml penicillin, 100  $\mu\text{g}/\text{ml}$  streptomycin,  $1\times$  minimum Eagle's medium vitamin solution, and 4 g/liter D-glucose. We acquired images with a Leica TCS SP8 laser-scanning confocal microscope with a temperature chamber. We recorded Grx1-roGFP2 emission between 496 and 535 nm (excitation at 405 and 488 nm) and subtracted autofluorescence in response to 405-nm excitation. At the end of each experiment, we added 2 mM DTT and 16 mM  $\text{H}_2\text{O}_2$  to fully reduce/oxidize the probe. We analyzed the images with Fiji Is Just ImageJ (Fiji) and excluded detached cells from the analysis. Ratios were normalized to percent oxidation as described previously (48).

## Cloning

We replaced the pgk-neo cassette in MSCVneo (Clontech Laboratories) with an IRES-GFP to generate GFP-RV. We excised the IRES-GFP from GFP-RV with EcoRI to generate RV2 and inserted a multiple cloning site (BglII, XhoI, NcoI, NotI, and EcoRI) between the original BglII/EcoRI sites. We amplified all constructs of Grx1-roGFP2 from pLPCX-Grx1-roGFP2, ASC from mouse cDNA, and Fv'Fvls from pSH1/Sn-E-Fv'Fvls-E. We generated the fusion constructs ASC-Grx1-roGFP2 and Fv'Fvls-ASC by overlapping PCRs. We cloned all sensors into RV2 at the NcoI/NotI sites and inserted the artificially dimerizable ASC fusion Fv'Fvls-ASC into GFP-RV using XhoI/SalI sites.

## Western blot analysis

We precipitated supernatants by mixing with methanol/chloroform and lysed BMDMs in 1% IGEPAL CA-630/PBS with cComplete EDTA-free protease inhibitor (Roche). Mouse monoclonal IgG2b (Cryo-2) anti-NLRP3 and mouse monoclonal IgG1 (Casper-1) anti-Caspase-1 were from AdipoGen. Rabbit polyclonal anti-IL-1 $\beta$  was from Abcam, mouse monoclonal IgG1 (DM1A) anti- $\alpha$ -tubulin was from Sigma-Aldrich, and secondary antibodies were from Jackson ImmunoResearch Laboratories.

*Author contributions*—S. V. W. and A. Z. conceptualization; S. V. W. data curation; S. V. W. formal analysis; S. V. W. validation; S. V. W. visualization; S. V. W. methodology; S. V. W. writing-original draft; A. Z. supervision; A. Z. project administration; A. Z. writing-review and editing.

*Acknowledgments*—pLPCX-Grx1-roGFP2 was a gift from Tobias Dick. pSH1/Sn-E-Fv'Fvls-E was a gift from David Spencer (Addgene plasmid 15274). We thank Baerbel Raupach and Gabriel Sollberger for critically reading the manuscript.

## References

1. de Zoete, M. R., Palm, N. W., Zhu, S., and Flavell, R. (2014) Inflammasomes. *Cold Spring Harb. Perspect. Biol.* **6**, a016287–a016287 [CrossRef](#) [Medline](#)
2. Muñoz-Planillo, R., Kuffa, P., Martínez-Colón, G., Smith, B. L., Rajendiran, T. M., and Núñez, G. (2013) K<sup>+</sup> efflux is the common trigger of

- NLRP3 inflammasome activation by bacterial toxins and particulate matter. *Immunity* **38**, 1142–1153 [CrossRef Medline](#)
3. Tschopp, J., and Schroder, K. (2010) NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? *Nat. Rev. Immunol.* **10**, 210–215 [CrossRef Medline](#)
  4. Abais, J. M., Xia, M., Zhang, Y., Boini, K. M., and Li, P.-L. (2015) Redox regulation of NLRP3 inflammasomes: ROS as trigger or effector? *Antioxid. Redox Signal.* **22**, 1111–1129 [CrossRef Medline](#)
  5. Gurung, P., Lukens, J. R., and Kanneganti, T.-D. (2015) Mitochondria: diversity in the regulation of the NLRP3 inflammasome. *Trends Mol. Med.* **21**, 193–201 [CrossRef Medline](#)
  6. Gellatly, S. L., and Hancock, R. E. (2013) *Pseudomonas aeruginosa*: new insights into pathogenesis and host defenses. *Pathog. Dis.* **67**, 159–173 [CrossRef Medline](#)
  7. Hall, S., McDermott, C., Anoopkumar-Dukie, S., McFarland, A. J., Forbes, A., Perkins, A. V., Davey, A. K., Chess-Williams, R., Kiefel, M. J., Arora, D., and Grant, G. D. (2016) Cellular effects of pyocyanin, a secreted virulence factor of *Pseudomonas aeruginosa*. *Toxins* **10**, 3390/toxins8080236
  8. Lau, G. W., Hassett, D. J., Ran, H., and Kong, F. (2004) The role of pyocyanin in *Pseudomonas aeruginosa* infection. *Trends Mol. Med.* **10**, 599–606 [CrossRef Medline](#)
  9. Rada, B., and Leto, T. L. (2013) Pyocyanin effects on respiratory epithelium: relevance in *Pseudomonas aeruginosa* airway infections. *Trends Microbiol.* **21**, 73–81 [CrossRef Medline](#)
  10. Baron, S. S., and Rowe, J. J. (1981) Antibiotic action of pyocyanin. *Antimicrob. Agents Chemother.* **20**, 814–820 [CrossRef Medline](#)
  11. Usher, L. R., Lawson, R. A., Geary, I., Taylor, C. J., Bingle, C. D., Taylor, G. W., and Whyte, M. K. (2002) Induction of neutrophil apoptosis by the *Pseudomonas aeruginosa* exotoxin pyocyanin: a potential mechanism of persistent infection. *J. Immunol.* **168**, 1861–1868 [CrossRef Medline](#)
  12. Rada, B., Jendrysik, M. A., Pang, L., Hayes, C. P., Yoo, D.-G., Park, J. J., Moskowitz, S. M., Malech, H. L., and Leto, T. L. (2013) Pyocyanin-enhanced neutrophil extracellular trap formation requires the NADPH oxidase. *PLoS ONE* **8**, e54205 [CrossRef Medline](#)
  13. Hunter, R. C., Klepac-Ceraj, V., Lorenzi, M. M., Grotzinger, H., Martin, T. R., and Newman, D. K. (2012) Phenazine content in the cystic fibrosis respiratory tract negatively correlates with lung function and microbial complexity. *Am. J. Respir. Cell Mol. Biol.* **47**, 738–745 [CrossRef Medline](#)
  14. Gutscher, M., Pauleau, A.-L., Marty, L., Brach, T., Wabnitz, G. H., Samstag, Y., Meyer, A. J., and Dick, T. P. (2008) Real-time imaging of the intracellular glutathione redox potential. *Nat. Methods.* **5**, 553–559 [CrossRef Medline](#)
  15. Fan, L., Freeman, K. W., Khan, T., Pham, E., and Spencer, D. M. (1999) Improved artificial death switches based on caspases and FADD. *Hum. Gene Ther.* **10**, 2273–2285 [CrossRef Medline](#)
  16. Heid, M. E., Keyel, P. A., Kanga, C., Shiva, S., Watkins, S. C., and Salter, R. D. (2013) Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal damage and inflammasome activation. *J. Immunol.* **191**, 5230–5238 [CrossRef Medline](#)
  17. Iyer, S. S., He, Q., Janczy, J. R., Elliott, E. I., Zhong, Z., Olivier, A. K., Sadler, J. J., Knepper-Adrian, V., Han, R., Qiao, L., Eisenbarth, S. C., Nauseef, W. M., Cassel, S. L., and Sutterwala, F. S. (2013) Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation. *Immunity* **39**, 311–323 [CrossRef Medline](#)
  18. Zhou, R., Yazdi, A. S., Menu, P., and Tschopp, J. (2011) A role for mitochondria in NLRP3 inflammasome activation. *Nature* **469**, 221–225 [CrossRef Medline](#)
  19. Ichinohe, T., Yamazaki, T., Koshiba, T., and Yanagi, Y. (2013) Mitochondrial protein mitofusin 2 is required for NLRP3 inflammasome activation after RNA virus infection. *Proc. Natl. Acad. Sci.* **110**, 17963–17968 [CrossRef Medline](#)
  20. Sorbara, M. T., and Girardin, S. E. (2011) Mitochondrial ROS fuel the inflammasome. *Cell Res.* **21**, 558–560 [CrossRef Medline](#)
  21. Pfeiffer, S., Schrammel, A., Koesling, D., Schmidt, K., and Mayer, B. (1998) Molecular actions of a Mn(III)porphyrin superoxide dismutase mimetic and peroxynitrite scavenger: reaction with nitric oxide and direct inhibition of NO synthase and soluble guanylyl cyclase. *Mol. Pharmacol.* **53**, 795–800 [CrossRef Medline](#)
  22. Yang, J., Lee, K.-M., Park, S., Cho, Y., Lee, E., Park, J.-H., Shin, O. S., Son, J., Yoon, S. S., and Yu, J.-W. (2017) Bacterial secretant from *Pseudomonas aeruginosa* dampens inflammasome activation in a quorum sensing-dependent manner. *Front. Immunol.* **8**, 333 [Medline](#)
  23. Zhou, Y., Zhao, D., Yue, R., Khan, S. H., Shah, S. Z., Yin, X., Yang, L., Zhang, Z., and Zhou, X. (2015) Inflammasome-dependent regulation of IL-1 $\beta$  secretion induced by the virulent *Mycobacterium bovis* Beijing strain in THP-1 macrophages. *Antonie Van Leeuwenhoek.* **108**, 163–171 [CrossRef Medline](#)
  24. O'Malley, Y. Q., Abdalla, M. Y., McCormick, M. L., Reszka, K. J., Denning, G. M., and Britigan, B. E. (2003) Subcellular localization of *Pseudomonas* pyocyanin cytotoxicity in human lung epithelial cells. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **284**, L420–L430 [CrossRef Medline](#)
  25. Managò, A., Becker, K. A., Carpinteiro, A., Wilker, B., Soddemann, M., Seitz, A. P., Edwards, M. J., Grassmé, H., Szabò, I., and Gulbins, E. (2015) *Pseudomonas aeruginosa* pyocyanin induces neutrophil death via mitochondrial reactive oxygen species and mitochondrial acid sphingomyelinase. *Antioxid. Redox Signal.* **22**, 1097–1110 [CrossRef Medline](#)
  26. Schwarzer, C., Fu, Z., Fischer, H., and Machen, T. E. (2008) Redox-independent activation of NF- $\kappa$ B by *Pseudomonas aeruginosa* pyocyanin in a cystic fibrosis airway epithelial cell line. *J. Biol. Chem.* **283**, 27144–27153 [CrossRef Medline](#)
  27. Ahmad, I. M., Britigan, B. E., and Abdalla, M. Y. (2011) Oxidation of thiols and modification of redox-sensitive signaling in human lung epithelial cells exposed to *Pseudomonas* pyocyanin. *J. Toxicol. Environ. Health. A.* **74**, 43–51 [Medline](#)
  28. Meissner, F., Molawi, K., and Zychlinsky, A. (2008) Superoxide dismutase 1 regulates caspase-1 and endotoxic shock. *Nat. Immunol.* **9**, 866–872 [CrossRef Medline](#)
  29. Zhao, C., Gillette, D. D., Li, X., Zhang, Z., and Wen, H. (2014) Nuclear factor E2-related factor-2 (Nrf2) is required for NLRP3 and AIM2 inflammasome activation. *J. Biol. Chem.* **289**, 17020–17029 [CrossRef Medline](#)
  30. Yu, J., Nagasu, H., Murakami, T., Hoang, H., Broderick, L., Hoffman, H. M., and Horng, T. (2014) Inflammasome activation leads to caspase-1-dependent mitochondrial damage and block of mitophagy. *Proc. Natl. Acad. Sci. U.S.A.* **111**, 15514–15519 [CrossRef Medline](#)
  31. Lambert, A. J., and Brand, M. D. (2004) Superoxide production by NADH: ubiquinone oxidoreductase (complex I) depends on the pH gradient across the mitochondrial inner membrane. *Biochem. J.* **382**, 511–517 [CrossRef Medline](#)
  32. Lambert, A. J., and Brand, M. D. (2004) Inhibitors of the quinone-binding site allow rapid superoxide production from mitochondrial NADH: ubiquinone oxidoreductase (complex I). *J. Biol. Chem.* **279**, 39414–39420 [CrossRef Medline](#)
  33. Liu, S. S. (1997) Generating, partitioning, targeting and functioning of superoxide in mitochondria. *Biosci. Rep.* **17**, 259–272 [CrossRef Medline](#)
  34. Rottenberg, H., Covian, R., and Trumpower, B. L. (2009) Membrane potential greatly enhances superoxide generation by the cytochrome bc1 complex reconstituted into phospholipid vesicles. *J. Biol. Chem.* **284**, 19203–19210 [CrossRef Medline](#)
  35. Nicholls, D. G. (2006) Simultaneous monitoring of ionophore- and inhibitor-mediated plasma and mitochondrial membrane potential changes in cultured neurons. *J. Biol. Chem.* **281**, 14864–14874 [CrossRef Medline](#)
  36. Johnson, L. V., Walsh, M. L., Bockus, B. J., and Chen, L. B. (1981) Monitoring of relative mitochondrial membrane potential in living cells by fluorescence microscopy. *J. Cell Biol.* **88**, 526–535 [CrossRef Medline](#)
  37. Yang, J., Liu, Z., and Xiao, T. S. (2017) Post-translational regulation of inflammasomes. *Cell. Mol. Immunol.* **14**, 65–79 [CrossRef Medline](#)
  38. Bednash, J. S., and Mallampalli, R. K. (2016) Regulation of inflammasomes by ubiquitination. *Cell. Mol. Immunol.* **13**, 722–728 [CrossRef Medline](#)
  39. Spalinger, M. R., Kasper, S., Gottier, C., Lang, S., Atrott, K., Vavricka, S. R., Scharl, S., Gutte, P. M., Grütter, M. G., Beer, H.-D., Contassot, E., Chan, A. C., Dai, X., Rawlings, D. J., Mair, F., et al. (2016) NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22. *J. Clin. Invest.* **126**, 1783–1800 [CrossRef Medline](#)

## Pyocyanin inhibits the NLRP3 inflammasome

40. Stutz, A., Kolbe, C.-C., Stahl, R., Horvath, G. L., Franklin, B. S., van Ray, O., Brinkschulte, R., Geyer, M., Meissner, F., and Latz, E. (2017) NLRP3 inflammasome assembly is regulated by phosphorylation of the pyrin domain. *J. Exp. Med.* 10.1084/jem.20160933
41. Lo Conte, M., and Carroll, K. S. (2013) The redox biochemistry of protein sulfenylation and sulfinylation. *J. Biol. Chem.* **288**, 26480–26488 [CrossRef Medline](#)
42. Tsai, S. J., Sen, U., Zhao, L., Greenleaf, W. B., Dasgupta, J., Fiorillo, E., Orrú, V., Bottini, N., and Chen, X. S. (2009) Crystal structure of the human lymphoid tyrosine phosphatase catalytic domain: insights into redox regulation. *Biochemistry* **48**, 4838–4845 [CrossRef Medline](#)
43. Allen, L., Dockrell, D. H., Pattery, T., Lee, D. G., Cornelis, P., Hellewell, P. G., and Whyte, M. K. (2005) Pyocyanin production by *Pseudomonas aeruginosa* induces neutrophil apoptosis and impairs neutrophil-mediated host defenses *in vivo*. *J. Immunol.* **174**, 3643–3649 [CrossRef Medline](#)
44. Lavoie, E. G., Wangdi, T., and Kazmierczak, B. I. (2011) Innate immune responses to *Pseudomonas aeruginosa* infection. *Microbes Infect.* **13**, 1133–1145 [CrossRef Medline](#)
45. Deng, Q., Wang, Y., Zhang, Y., Li, M., Li, D., Huang, X., Wu, Y., Pu, J., and Wu, M. (2015) *Pseudomonas aeruginosa* triggers macrophage autophagy to escape intracellular killing by activation of the NLRP3 inflammasome. *Infect. Immun.* **84**, 56–66 [CrossRef Medline](#)
46. Rimessi, A., Bezzerri, V., Patergnani, S., Marchi, S., Cabrini, G., and Pinton, P. (2015) Mitochondrial Ca<sup>2+</sup>-dependent NLRP3 activation exacerbates the *Pseudomonas aeruginosa*-driven inflammatory response in cystic fibrosis. *Nat. Commun.* **6**, 6201 [CrossRef Medline](#)
47. Hughes, A. J., and Hauser, A. R. (2015) *Pseudomonas* activation of the inflammasome. in *Pseudomonas* (Ramos, J. L., Goldberg, J., and Filloux, A., eds) pp. 51–74, Springer, Dordrecht, Netherlands [CrossRef](#)
48. Meyer, A. J., and Dick, T. P. (2010) Fluorescent protein-based redox probes. *Antioxid. Redox Signal.* **13**, 621–650 [CrossRef Medline](#)

## **The bacterial pigment pyocyanin inhibits the NLRP3 inflammasome through intracellular reactive oxygen and nitrogen species**

Sebastian Virreira Winter and Arturo Zychlinsky

*J. Biol. Chem.* 2018, 293:4893-4900.

doi: 10.1074/jbc.RA117.001105 originally published online February 6, 2018

---

Access the most updated version of this article at doi: [10.1074/jbc.RA117.001105](https://doi.org/10.1074/jbc.RA117.001105)

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

This article cites 48 references, 19 of which can be accessed free at <http://www.jbc.org/content/293/13/4893.full.html#ref-list-1>

**The bacterial pigment pyocyanin inhibits the NLRP3 inflammasome through  
intracellular ROS/RNS**

*Sebastian Virreira Winter & Arturo Zychlinsky*

**Supplemental Data**

Supplementary Figure S1: S-2


Supplementary Figure S2: S-3

Supplementary Figure S3: S-4

Supplementary Figure S4: S-5

Supplementary Figure S5: S-6

## Supplementary Figure S1




### Supplementary Figure S1


**(A)** We first pretreated LPS-primed BMDMs with 100 ng/ml of LPS for three hours and then added DMSO as a control or 100  $\mu$ M PCN for 15 min. We quantified mRNA expression levels of the indicated cytokines by qRT-PCR. The mRNA fold changes are in relation to the levels in naive BMDMs. **(B)** We first treated BMDMs with DMSO or 100  $\mu$ M PCN for 15 minutes and then primed the cells with 100 ng/ml LPS for three hours. The mRNA levels were determined as in (A). Graphs show means + SD from three independent replicates. A paired Student's t-test with Benjamini-Hochberg correction was performed for statistical analysis (significance cut-off was 0.05).

## Supplementary Figure S2


**A**



**C**



**B**




### Supplementary Figure S2


**(A)** We first pretreated LPS-primed BMDMs with the indicated concentrations of the translation inhibitor cycloheximide (CHX) for 15 minutes, and then incubated them with 100 ng/ml of LPS. We quantified TNF release (ELISA) and pyroptosis (intracellular LDH content) after 2 hours. **(B)** We pretreated LPS-primed BMDMs expressing ASC-Grx1-roGFP2 with 0 μM or 60 μM PCN for 15 minutes before we activated NLRP3 by adding 10 μM nigericin. Speck formation was observed by time-lapse confocal microscopy. Cells were excited with a 488 nm laser and emission was recorded between 496-535 nm. **(C)** We treated LPS-primed BMDMs expressing FvFvls-ASC with 0,20,40,60,80 or 100 μM PCN for 15 minutes and induced speck formation with the B/B homodimerizer (AP20187). Graphs in (A) & (C) show means + SD and are from one representative experiment of two independent replicates. Repeated measures one-way ANOVA on two independent replicates was performed for statistical analysis. Pictures in (B) are representatives from four independent experiments.

## Supplementary Figure S3

**A**



**B**




### Supplementary Figure S3


(A) We loaded BMDMs with 5 μM of the oxidation-sensitive dyes CM-H<sub>2</sub>-DCFDA or Dihydroethidium (DHE) before incubating them with 0, 20, 40, 60, 80, or 100 μM of the indicated phenazine for 30 minutes. We quantified fluorescence intensities by flow cytometry. Graphs show geometric mean + SEM from one representative experiment of three independent replicates. (B) We pretreated LPS-primed BMDMs with 0, 20, 40, 60, 80 or 100 μM of the indicated phenazines for 15 minutes and activated NLRP3 with by adding 10 μM nigericin. We quantified IL-1β release (ELISA) and pyroptosis (intracellular LDH content) after 1 hour. Graphs show mean + SD from one representative experiment of three independent replicates. Repeated measures one-way ANOVA was performed on the three independent replicates for statistical analysis.

## Supplementary Figure S4

A



B




### Supplementary Figure S4

(A) We treated BMDMs expressing Grx1-roGFP2 in the cytosol, the mitochondria, the nucleus or at the plasma membrane with 40 μM PCN and recorded the sensor fluorescence. Images show representative images just before (0 min) or 30 min after stimulation. The fluorescence signal in response to 405 nm excitation is false-colored in green and the fluorescence signal in response to 488 nm excitation is false-colored in red.

(B) We stimulated BMDMs expressing Grx1-roGFP2 within mitochondria with a vehicle control or 10 μM nigericin at timepoint 0 and recorded the sensor fluorescence. We calculated the percentage of oxidized sensor by determining the dynamic range at the end of the stimulation. Graphs indicate median oxidation of all cells analyzed for 1 hour.

## Supplementary Figure S5



### Supplementary Figure S5

BMDMs expressing FLAG-tagged NLRP3 were primed with 100 ng/ml LPS for three hours and then treated with 100  $\mu$ M PCN or DMSO as a control for 15 minutes. Reduced and reversibly oxidized cysteines were differentially alkylated with the cysteine-reactive isobaric tag iodoTMT to determine the oxidation state of individual cysteines. The samples were digested with trypsin and peptides were analyzed by MS/MS. Graphs show mean + SD from individual MS/MS scans of two independent replicates. n.d. = not determined.